Test Price
2,800 AED✅ Home Collection Available
FBXO7 Gene PARK15 Parkinson Genetic Test in UAE | 2800 AED | DHA-Certified Genomic Testing
Executive Summary & Core Metrics
This advanced NGS-based genetic test delivers a comprehensive assessment of the FBXO7 gene, the established causative locus for PARK15 juvenile-onset parkinsonism. Processed exclusively within our ISO 9001:2015-certified genomic facility (Cert: INT/EGQ/2509DA/3139), this assay provides neurologists, clinical geneticists, and medical researchers with definitive molecular confirmation for differential diagnosis of early-onset movement disorders.
Test Overview & Methodology
The FBXO7 gene, located on chromosome 22q12.3, encodes the F-box only protein 7, a critical component of the ubiquitin-proteasome system implicated in mitochondrial maintenance and dopaminergic neuron survival. Pathogenic biallelic variants in FBXO7 cause autosomal recessive juvenile-onset parkinsonism (PARK15), characterized by early pyramidal signs, levodopa-responsive parkinsonism, and progressive motor deterioration.
This test employs Next-Generation Sequencing (NGS) with complete coding region coverage of FBXO7, including all exons and exon-intron boundaries (±20 bp), achieving greater than 99.5% analytical sensitivity for single nucleotide variants, small insertions/deletions, and copy number variations at a minimum read depth of 100×.
| Parameter | Our FBXO7 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity — Full Gene Coverage | ~95% — Limited to Targeted Exons Only |
| Methodology | NGS (Next-Generation Sequencing) with CNV Analysis | Bidirectional Sanger Sequencing — No CNV Detection |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks (Multi-Exon Sequential Analysis) |
| Sample Flexibility | Whole Blood, Extracted DNA, or Dried Blood Spot (FTA Card) | Whole Blood or Extracted DNA Only |
| Clinical Reporting | Comprehensive — ACMG Variant Classification, Clinical Correlation, Cascade Screening Guidance | Basic — Variant Call with Minimal Interpretation |
| UAE Regulatory Compliance | Full — DHA, MOHAP, ISO 9001:2015, UAE PDPL | Variable — Often Lacks UAE-Specific Accreditation |
Physician Insight & Safety Protocols
"As a Consultant Medical Genetics practicing in the UAE, I emphasize that the FBXO7 PARK15 NGS test provides robust molecular confirmation of this specific genetic subtype of juvenile-onset parkinsonism. A positive result enables targeted therapeutic planning, informed prognostic counseling, and cascade screening for at-risk family members. However, genetic test results must always be contextualized within the full clinical picture — including neurological examination, neuroimaging, and comprehensive family history. A negative result does not rule out other genetic or idiopathic forms of parkinsonism, and I strongly recommend all patients review their results with their treating neurologist and a qualified clinical geneticist before implementing any management changes."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Medication Advisory
Do not discontinue, modify, or adjust the dosage of any prescribed medication — including levodopa/carbidopa, dopamine agonists, MAO-B inhibitors, or any antiparkinsonian therapy — without consulting your treating physician. Abrupt withdrawal of dopaminergic medications may precipitate neuroleptic malignant-like syndrome, severe rigidity, or life-threatening autonomic instability.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed If:
- Patient is under 18 years of age without court-appointed guardian consent.
- Inability to provide valid UAE Emirates ID or passport for identity verification.
- Active febrile illness or acute infection at time of sample collection — reschedule after recovery.
- Recent blood transfusion (within 4 weeks) — may confound germline DNA analysis.
- Absence of documented clinical indication or specialist referral as required under Federal Law No. 2 of 2019.
Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden worsening of motor symptoms with confusion or altered consciousness.
- Severe muscle rigidity with hyperthermia — possible neuroleptic malignant-like syndrome.
- Acute respiratory distress or aspiration pneumonia.
- Psychotic symptoms, hallucinations, or severe impulse control disorder.
- Unexplained falls with head trauma in parkinsonian patients.
Patient FAQ & Clinical Guidance
1. What is the FBXO7 PARK15 Genetic Test, and why is it clinically recommended?
The FBXO7 PARK15 NGS test is a high-precision molecular diagnostic assay that detects pathogenic mutations in the FBXO7 gene responsible for autosomal recessive juvenile-onset Parkinson's disease with 99.9% diagnostic sensitivity. Clinically, it is recommended for patients presenting with early-onset parkinsonism (before age 40), particularly those exhibiting pyramidal tract signs, levodopa-responsive motor symptoms, and a positive family history suggesting autosomal recessive inheritance. Definitive genetic confirmation enables personalized treatment planning, prognostic counseling, and cascade screening of at-risk family members to identify pre-symptomatic carriers.
2. How is the FBXO7 PARK15 Genetic Test performed, and what is the sample collection process in the UAE?
A DHA-licensed phlebotomist performs a simple venous blood draw (3-5 mL) during a scheduled home visit, or alternatively a single-drop blood spot on an FTA card is collected for pediatric and remote-area patients, with all samples transported under ISO-certified cold-chain to our genomic laboratory for NGS analysis with a 3-to-4-week turnaround. The home collection service operates daily from 8 AM to 11 PM across all seven emirates, ensuring maximum convenience for patients with mobility challenges. Once the sample arrives at our facility, DNA is extracted, quantified, and subjected to targeted NGS enrichment covering the entire FBXO7 coding region, followed by bioinformatics analysis aligned to the GRCh38/hg38 reference genome and variant classification per ACMG/AMP guidelines.
3. What do the FBXO7 PARK15 genetic test results mean for my long-term health and family planning?
A positive pathogenic or likely pathogenic FBXO7 result confirms PARK15-linked juvenile parkinsonism, guiding neurologists toward optimized levodopa and adjunctive therapy while prompting genetic counseling for family members regarding autosomal recessive inheritance with a 25% recurrence risk in future pregnancies. A negative result rules out FBXO7 as the causative gene but does not exclude other genetic or idiopathic forms of parkinsonism, necessitating continued neurological follow-up and potential broader panel testing or whole-exome sequencing. Variants of uncertain significance require periodic reclassification as new scientific evidence emerges, and family segregation studies may be recommended to clarify pathogenicity. All results are disclosed through a structured genetic counseling session to ensure psychological preparedness and informed decision-making regarding reproductive options, including preimplantation genetic testing if desired.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 (PDPL)
All genomic data is encrypted, stored on UAE-sovereign servers, and never shared with third parties without explicit consent. Full compliance with the UAE Personal Data Protection Law.
Federal Law No. 2 of 2019 (Health ICT)
Strict adherence to regulations governing the use of information and communication technology in health fields, ensuring secure handling of all electronic health records and genetic data.
Federal Decree-Law No. 4 of 2016 (Medical Liability)
Clinical testing safety and patient consent procedures follow this law, ensuring all genetic testing is performed under informed consent with full disclosure of risks, benefits, and implications.
ISO 9001:2015 Certification: Cert: INT/EGQ/2509DA/3139 — Quality Management System audited annually. Facility License: 1143 — DHA/MOHAP Registered Genomic Testing Facility.
Clinical & Logistical Metadata
| Test Name | FBXO7 Gene PARK15 Parkinson Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (3-5 mL EDTA), Extracted DNA (≥1 μg at ≥50 ng/μL), or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV Analysis, minimum 100× read depth |
| ICD-10-CM Code | G20 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DHA Facility License Number: 1143 | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians